In Vitro ADME
Metabolic stability in liver microsomes and hepatocytes. Plasma protein binding and permeability assessment (e.g., Caco-2, PAMPA systems). CYP interaction screening as needed to evaluate drug-drug interaction potential.
In Vivo Pharmacokinetics
PK studies in rodent species (and non-rodent via qualified partners) with dose-dependent exposure assessment. Bioavailability determination across administration routes. PK/PD relationship establishment supporting dose selection for efficacy and toxicology programs.
Metabolite Profiling
LC-MS/MS analysis identifying major metabolic pathways and metabolites of interest. Cross-species comparison supporting human PK predictions where applicable.